CoChat

Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol

Open access

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Patients with implantable cardioverter-defibrillators often receive adjunctive antiarrhythmic therapy to prevent frequent shocks. We tested the efficacy and safety of sotalol, a beta-blocker with class III antiarrhythmic effects, for this purpose. METHODS: In a multicenter trial, patients were stratified according to left ventricular ejection fraction (< or =0.30 or >0.30), randomly assigned to double-blind treatment with 160 to 320 mg of sotalol per day (151 patients) or matching placebo (151 patients), and followed for 12 months. Kaplan-Meier analyses of the time to an event were performed. Three end points were used: the delivery of a first shock for any reason or death from any cause, the first appropriate shock for a ventricular arrhythmia or death from any cause, and the first inappropriate shock for a supraventricular arrhythmia or death from any cause. RESULTS: Compliance with double-blind treatment was similar in the two groups. There were seven deaths in the placebo group and four in the sotalol group. As compared with placebo, treatment with sotalol was associated with a lower risk of death from any cause or the delivery of a first shock for any reason (reduction in risk, 48 percent; P<0.001 by the log-rank test), death from any cause or the delivery of a first appropriate shock (reduction in risk, 44 percent; P=0.007), or death from any cause or the delivery of a first inappropriate shock (reduction in risk, 64 percent; P=0.004). Sotalol also reduced the mean (+/-SD) frequency of shocks due to any cause (1.43+/-3.53 shocks per year, as compared with 3.89+/-10.65 in the placebo group; P=0.008). In the sotalol group, the reduction in the risk of death from any cause or the delivery of a first shock for any reason did not differ significantly between patients with ejection fractions of more than 0.30 and those with ejection fractions of 0.30 or less. CONCLUSIONS: Oral sotalol was safe and efficacious in reducing the risk of death or the delivery of a first defibrillator shock whether or not ventricular function was depressed.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm199906173402402

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 443

Metadata

Authors
Pacifico, A., Hohnloser, S. H., Williams, J. H., Tao, B., Saksena, S., Henry, P. D., & Prystowsky, E. N.
Affiliations
  • Goethe University Frankfurt (DE)
  • St Vincent Hospital (US)
Venue
New England Journal of Medicine
Published
1999-06-17
Volume
340
Issue
24
Pages
1855-1862
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2002864523
Cited by
422
References
26
Citations by year
2026: 5 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 10 · 2021: 10 · 2020: 8 · 2019: 17 · 2018: 13 · 2017: 26 · 2016: 17 · 2015: 15 · 2014: 10 · 2013: 22 · 2012: 10
FWCI
15.26
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
Keywords
sotalol, implantable cardioverter-defibrillator, inappropriate shocks, antiarrhythmic therapy, beta-blockers, class III antiarrhythmic agents, left ventricular ejection fraction, ventricular arrhythmias, mortality, shock prevention
MeSH terms
Adrenergic beta-Antagonists, Adult, Aged, Anti-Arrhythmia Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Sotalol, Stroke Volume, Tachycardia, Survival Analysis, Chemotherapy, Adjuvant, Defibrillators, Implantable

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol. https://app.cochat.ai/papers/10.1056/nejm199906173402402
The paper
Pacifico, A., Hohnloser, S. H., Williams, J. H., Tao, B., Saksena, S., Henry, P. D., & Prystowsky, E. N. (1999). Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol. New England Journal of Medicine. https://doi.org/10.1056/nejm199906173402402

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.